{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:08:32Z","timestamp":1793214512908,"version":"4.5.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1002901","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T18:21:34Z","timestamp":1568312494000},"page":"e1002901","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":129,"title":["Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3487-8551","authenticated-orcid":true,"given":"Piero","family":"Ruscitti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-5324","authenticated-orcid":true,"given":"Francesco","family":"Masedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Alvaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Air\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Battafarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":true,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Cantatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"D'Abrosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micol","family":"Frassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Iacono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Liakouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Mul\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Pantano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immacolata","family":"Prevete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5502-630X","authenticated-orcid":true,"given":"Luigi","family":"Sinigaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0670-9638","authenticated-orcid":true,"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"issue":"4","key":"pmed.1002901.ref001","first-page":"CD007848","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane reviews.","author":"JA Singh","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"pmed.1002901.ref002","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrrheum.2015.112","article-title":"Cardiovascular comorbidity in rheumatic diseases","volume":"11","author":"MT Nurmohamed","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"pmed.1002901.ref003","doi-asserted-by":"crossref","first-page":"e7896","DOI":"10.1097\/MD.0000000000007896","article-title":"Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study","volume":"96","author":"P Ruscitti","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"pmed.1002901.ref004","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrd4275","article-title":"Targeting inflammation in the treatment of type 2 diabetes: time to start.","volume":"13","author":"MY Donath","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"pmed.1002901.ref005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/bs.acc.2016.02.001","article-title":"Cytokines and Pancreatic \u03b2-Cell Apoptosis","volume":"75","author":"LA Berchtold","year":"2016","journal-title":"Adv Clin Chem"},{"key":"pmed.1002901.ref006","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1586\/1744666X.2016.1168293","article-title":"IL-1\u03b2 at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?","volume":"12","author":"R Giacomelli","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"pmed.1002901.ref007","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jamainternmed.2014.5841","article-title":"Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis","volume":"175","author":"M Viswanathan","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"Suppl 2","key":"pmed.1002901.ref008","first-page":"ii32","article-title":"Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?","volume":"63","author":"T Pincus","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"pmed.1002901.ref009","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","article-title":"EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases","volume":"72","author":"N Duru","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"pmed.1002901.ref010","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa065213","article-title":"Interleukin-1-receptor antagonist in type 2 diabetes mellitus","volume":"356","author":"CM Larsen","year":"2007","journal-title":"N Engl J Med"},{"key":"pmed.1002901.ref011","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/009286150103500407","article-title":"Flexible sample size considerations using information-based interim monitoring","volume":"35","author":"CR Mehta","year":"2001","journal-title":"Drug Information Journal"},{"key":"pmed.1002901.ref012","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1136\/bmj.322.7286.603","article-title":"Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility","volume":"322","author":"M Li\u00e8vre","year":"2001","journal-title":"BMJ"},{"key":"pmed.1002901.ref013","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/bmj.305.6847.235","article-title":"When to stop a clinical trial","volume":"305","author":"SJ Pocock","year":"1992","journal-title":"BMJ"},{"key":"pmed.1002901.ref014","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.294.17.2203","article-title":"Randomized trials stopped early for benefit: a systematic review","volume":"294","author":"VM Montori","year":"2005","journal-title":"JAMA"},{"key":"pmed.1002901.ref015","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00296-018-4041-1","article-title":"Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis","volume":"38","author":"S Nikfar","year":"2018","journal-title":"Rheumatol Int"},{"key":"pmed.1002901.ref016","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc09-0533","article-title":"Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes","volume":"32","author":"CM Larsen","year":"2009","journal-title":"Diabetes Care"},{"key":"pmed.1002901.ref017","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(13)60023-9","article-title":"Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials","volume":"381","author":"A Moran","year":"2013","journal-title":"Lancet"},{"key":"pmed.1002901.ref018","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1073\/pnas.0611487104","article-title":"The Fas pathway is involved in pancreatic beta cell secretory function","volume":"104","author":"DM Schumann","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pmed.1002901.ref019","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/cei.12667","article-title":"Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1beta via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients","volume":"182","author":"P Ruscitti","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"pmed.1002901.ref020","first-page":"1316","article-title":"No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients","volume":"85","author":"N Paquot","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"pmed.1002901.ref021","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/oby.2004.86","article-title":"Lowered tumor necrosis factor receptors, but not increased insulin sensitivity, with infliximab","volume":"12","author":"P Di Rocco","year":"2004","journal-title":"Obes Res"},{"key":"pmed.1002901.ref022","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.2009.05287.x","article-title":"Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy","volume":"1193","author":"MA Gonzalez-Gay","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"pmed.1002901.ref023","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.2010.310","article-title":"Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis","volume":"303","author":"D Bassler","year":"2010","journal-title":"JAMA"},{"key":"pmed.1002901.ref024","first-page":"339","volume-title":"The Nazi doctors and the Nuremberg code: human rights in human experimentation","author":"IV Declaration of Helsinki","year":"1992"},{"key":"pmed.1002901.ref025","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/bjc.1976.220","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design","volume":"34","author":"R Peto","year":"1976","journal-title":"Br J Cancer"},{"key":"pmed.1002901.ref026","doi-asserted-by":"crossref","first-page":"e0181203","DOI":"10.1371\/journal.pone.0181203","article-title":"Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study","volume":"12","author":"P Ruscitti","year":"2017","journal-title":"PLoS ONE"},{"key":"pmed.1002901.ref027","doi-asserted-by":"crossref","first-page":"e0117952","DOI":"10.1371\/journal.pone.0117952","article-title":"The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta- analysis","volume":"10","author":"LR Baghdadi","year":"2015","journal-title":"PLoS ONE"},{"key":"pmed.1002901.ref028","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.24836","article-title":"Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study","volume":"61","author":"MJ Peters","year":"2009","journal-title":"Arthritis Rheum"},{"key":"pmed.1002901.ref029","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"KK Ray","year":"2009","journal-title":"Lancet"},{"key":"pmed.1002901.ref030","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"PM Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"pmed.1002901.ref031","first-page":"92","article-title":"Biological Response Modifiers in Rheumatoid Arthritis: Systematic Review and Meta-analysis of Safety","volume":"8","author":"ND Tank","year":"2017","journal-title":"J Pharmacol Pharmacother"},{"key":"pmed.1002901.ref032","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.amjmed.2014.06.012","article-title":"The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials","volume":"127","author":"TL Michaud","year":"2014","journal-title":"Am J Med"},{"key":"pmed.1002901.ref033","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/jps.24253","article-title":"Head to head comparison of the formulation and stability of concentrated solutions of HESylated versus PEGylated anakinra","volume":"104","author":"R Liebner","year":"2015","journal-title":"J Pharm Sci"},{"key":"pmed.1002901.ref034","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis","volume":"117","author":"I Ikonomidis","year":"2008","journal-title":"Circulation"},{"key":"pmed.1002901.ref035","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/dom.12357","article-title":"The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance","volume":"16","author":"PC van Poppel","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"pmed.1002901.ref036","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"MY Donath","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"pmed.1002901.ref037","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/art.38652","article-title":"Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis","volume":"66","author":"MC de Rotte","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"pmed.1002901.ref038","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.33378","article-title":"Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction","volume":"64","author":"D den Uyl","year":"2012","journal-title":"Arthritis Rheum"},{"key":"pmed.1002901.ref039","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1136\/ard.2011.151464","article-title":"Glucose tolerance, insulin sensitivity and \u03b2-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids","volume":"70","author":"JN Hoes","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"pmed.1002901.ref040","doi-asserted-by":"crossref","first-page":"e87965","DOI":"10.1371\/journal.pone.0087965","article-title":"Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study","volume":"9","author":"AM van Sijl","year":"2014","journal-title":"PLoS ONE"},{"key":"pmed.1002901.ref041","doi-asserted-by":"crossref","first-page":"e0210459","DOI":"10.1371\/journal.pone.0210459","article-title":"Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis","volume":"14","author":"S Lillegraven","year":"2019","journal-title":"PLoS ONE"},{"key":"pmed.1002901.ref042","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/520609a","article-title":"Personalized medicine: Time for one-person trials","volume":"520","author":"NJ Schork","year":"2015","journal-title":"Nature"},{"key":"pmed.1002901.ref043","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.rdc.2017.04.008","volume":"43","author":"J Bluett","year":"2017","journal-title":"Precision Medicine in Rheumatoid Arthritis. Rheum Dis Clin North Am"},{"key":"pmed.1002901.ref044","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kev421","article-title":"Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability.","volume":"55","author":"BV Cuppen","year":"2016","journal-title":"Rheumatology (Oxford)."},{"key":"pmed.1002901.ref045","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"GR Burmester","year":"2017","journal-title":"Lancet"},{"key":"pmed.1002901.ref046","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00125-016-3873-z","article-title":"Multiple benefits of targeting inflammation in the treatment of type 2 diabetes","volume":"59","author":"MY Donath","year":"2016","journal-title":"Diabetologia"},{"key":"pmed.1002901.ref047","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.2337\/dc15-2229","article-title":"Trends in Insulin Use and Diabetes Control in the U.S.: 1988\u20131994 and 1999\u20132012","volume":"39","author":"E Selvin","year":"2016","journal-title":"Diabetes Care"},{"key":"pmed.1002901.ref048","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2474-12-153","article-title":"Efficacy and safety of the human anti-IL-1\u03b2 monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.","volume":"12","author":"R Alten","year":"2011","journal-title":"BMC Musculoskeletal Disorders"},{"key":"pmed.1002901.ref049","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.2337\/dc11-2219","article-title":"Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes","volume":"35","author":"C Cavelti-Weder","year":"2012","journal-title":"Diabetes Care"},{"key":"pmed.1002901.ref050","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1463-1326.2012.01637.x","article-title":"Global Investigators. Effect of anti-IL-1\u03b2 anti-body (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial","volume":"14","author":"A Rissanen","year":"2012","journal-title":"Diabetes Obes Metab"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1002901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:09:02Z","timestamp":1588964942000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1002901"}},"subtitle":[],"editor":[{"given":"Sanjay","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1002901","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,12]]}}}